Targeting sensory nerves in the tumor microenvironment: a new vulnerability in cancer therapy.
Tumor innervation, the infiltration of nerves into the tumor microenvironment (TME), is increasingly recognized as a novel hallmark driving cancer progression and is associated with poor patient progn
APA
Jiang J, Xu Z, et al. (2026). Targeting sensory nerves in the tumor microenvironment: a new vulnerability in cancer therapy.. Cell communication and signaling : CCS, 24(1). https://doi.org/10.1186/s12964-025-02637-7
MLA
Jiang J, et al.. "Targeting sensory nerves in the tumor microenvironment: a new vulnerability in cancer therapy.." Cell communication and signaling : CCS, vol. 24, no. 1, 2026.
PMID
41612398
Abstract
Tumor innervation, the infiltration of nerves into the tumor microenvironment (TME), is increasingly recognized as a novel hallmark driving cancer progression and is associated with poor patient prognosis across various solid malignancies. This process is orchestrated by a complex, bidirectional crosstalk. Cancer and stromal cells release neurotrophic factors that induce axonogenesis or neurogenesis. In turn, the infiltrating nerves, particularly sensory nerves, secrete neurotransmitters, neuropeptides or form pseudo-synapse with tumor cells to facilitate cancer hallmarks, including sustained proliferation, invasion, metastasis, modulation of the anti-tumor immune response, and cancer plasticity. However, the specific contributions and underlying mechanisms of sensory nerve innervation in orchestrating malignancy remain incompletely elucidated. This review aims to synthesize the current understanding of the multifaceted roles of sensory neurons within the TME, detailing their intricate interactions with cancer and stromal cells, and highlighting the emerging therapeutic strategies that target the sensory nerve-tumor axis.
MeSH Terms
Humans; Tumor Microenvironment; Neoplasms; Sensory Receptor Cells; Animals
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and Safety of Different Dosages of Anlotinib Combined with PD-1 Monoclonal Antibody in the Treatment of Advanced Non-Small Cell Lung Cancer.
- DNMT1 and DNMT3A drive hepatocellular carcinoma progression via epigenetic regulation and are inhibited by 5-azacytidine.
- STC2 promotes colorectal cancer progression via c-Myc-mediated glycolysis and the PI3K/AKT/mTOR pathway.
- Recapitulating lung cancer metastasis : Advances in organoid models and challenges in clinical translation (Review).
- Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis.